Natural killer cell-based immunotherapy with CTLA4Ig-primed donor lymphocytes following haploidentical transplantation.

Abstract

NK cell-based immunotherapy is one of the more exciting propositions in the field of cellular therapy for hematological malignancies. Current protocols are largely based on expanded and activated NK cells which are used both with and without allogeneic transplantation. Based on our recent findings, we discuss the concept of CTLA4Ig-primed donor lymphocyte infusions following haploidentical transplantation as an effective tool to garner NK cell-mediated antitumor effect with abrogation of T cell-mediated alloreactivity. This approach might widen the possibility of immunotherapy following haploidentical transplantation without increase in graft-versus-host disease. Further studies would be needed to establish the veracity of this concept with better understanding of the antitumor effect via this pathway. Future studies would decide if CTLA4Ig might be used to augment NK-cell activation in vitro as well.

• Authors: Sarita Rani Jaiswal, Suparno Chakrabarti
• Journal: Immunotherapy (Immunotherapy) Vol. 11 Issue 14 Pg. 1221-1230 (10 2019) ISSN: 1750-7448 [Electronic] England
• PMID: 31478424 (Publication Type: Journal Article)

Chemical References

• Abatacept

Topics

• Abatacept (therapeutic use)
• Graft vs Host Disease (immunology, pathology, prevention & control)
• Hematologic Neoplasms (immunology, pathology, therapy)
• Hematopoietic Stem Cell Transplantation
• Humans
• Immunotherapy
• Killer Cells, Natural (immunology, pathology)
• Lymphocyte Transfusion
• Tissue Donors
• Transplantation, Haploidentical